<DOC>
	<DOC>NCT00667602</DOC>
	<brief_summary>The primary immunogenicity objective is to assess and compare the immunogenicity of one dose of MenACWY to one dose of Menjugate given to healthy toddlers at 12 months of age as measured by the percentage of subjects with serum bactericidal titers directed against N. meningitidis serogroup C â‰¥ 1:8 obtained in the serum bactericidal assay using human complement (hSBA).</brief_summary>
	<brief_title>Safety and Immunogenicity Evaluation After One or Two Doses of Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants and Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningitis, Meningococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>infants 6 to 8 months old inclusive, who were born after full term pregnancy and previously received three doses of both Prevenar and Infanrixhexa vaccines at least 30 days before study entry who previously received any meningococcal vaccine; who have had a previous confirmed or suspected disease caused by N. meningitidis, C. diphtheriae, C. tetani, Poliovirus, Hepatitis B, Hib, Pneumococcus or B. pertussis; who have had household contact with and/or intimate exposure to an individual with laboratory confirmed N. meningitidis (serogroups A, C, W135, or Y), B. pertussis, Hib, C. diphtheriae, Polio, or pneumococcal infection at any time since birth; Subjects with any serious, acute or chronic progressive disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>8 Months</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Meningococcal</keyword>
	<keyword>ACWY</keyword>
	<keyword>Conjugate Vaccine</keyword>
	<keyword>Meningitis</keyword>
	<keyword>Toddlers</keyword>
	<keyword>Infants</keyword>
	<keyword>Concomitant Vaccination</keyword>
</DOC>